| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.8 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.0071 | 0.8 |